Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab autoinjector self-administration in severe eosinophilic asthma (Study 204959)
2016-001832-36Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in eosinophilic asthma (EA) and asthma, sponsored by GSK. Primary endpoint: Proportion of subjects successfully able to self-administer their observed third dose. Started Mar 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)asthma
Beyond the preview
Go deeper on 2016-001832-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001832-36.